Partner With Us NRI

Alembic Pharmaceuticals Ltd share Price Today

Company details

6M Return 17.66%
1Y Return 51.32%
Mkt Cap.(Cr) 17,458.73
Volume 154,091
Div Yield 1.24%
OI Chg %
Volume 154,091

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Muted numbers; Cautious outlook with overheads recalibration…
About The Stock

    Alembic Pharma operates in international generics (US:28% & exUS: 15% in FY23), domestic branded (35% in FY23) and API (21% in FY23). Domestic business has 1.5% of market share of IPM with three brands in the top 300. Going ahead, emphasis is on the specialty segment

Q4FY23 Results

    Revenue impacted, margins still below par.

    • Revenues de-grew 0.7% YoY at ₹ 1,406 crore.

    • EBITDA grew 32.3% YoY to ₹ 211.8 crore whereas margins showed an improvement of 375 bps YoY to 15.1%.

    • Adjusted PAT came at ₹ 152.2 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Alembic Pharmaceuticals announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Net Sales increased 8% to Rs 1,517 crore.
  • Net Profit up 17% to Rs 178 crore
  • EBITDA up 29% to Rs 263 crore

FY24 Financial Highlights:

  • Net Sales grew 10% to Rs 6,229 crore.
  • Net Profit up 80% to Rs 616 crore
  • EBITDA up 41% to Rs 961 crore. 

Shaunak Amin, MD, Alembic Pharmaceuticals said “India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth. The outlook for the US business appears better, with the commercialization of new facilities and launches set to scale up along with continued progress in achieving cost improvements. The Ex-US generics and the API business maintained a steady continuous growth.”

Result PDF

View Other Company Results

Alembic Pharmaceuticals Ltd shares SWOT Analysis

Strengths (7)

  • Strong Annual EPS Growth
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
  • Company with Low Debt

Weakness (1)

  • Decline in Net Profit (QoQ)

Opportunity (1)

  • High Volume, High Gain

Threats (2)

  • Increasing Trend in Non-Core Income
  • RSI indicating price weakness

Resistance and support

R1 903.9
R2 919.6
R3 929.2


S1 878.6
S2 869.0
S3 853.3
Delivery and volume
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-10-11 611.25 184251 BSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-10-11 611.25 25903 BSE
Name Category Shares
Chirayu Ramanbhai Amin PROMOTER 2.13%
Malika Chirayu Amin PROMOTER 1.53%
Pranav Chirayu Amin PROMOTER 0.51%
Shaunak Chirayu Amin PROMOTER 0.51%
Nirayu Limited PROMOTER 35.63%
Alembic Limited PROMOTER 28.54%
Udit Chirayu Amin PROMOTER 0.51%


Investment recommendation
Muted numbers; Cautious outlook with overheads recalibration…
Call Date
08 May 2023
Entry Price 555.00
Target Price 530.00
12 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Alembic Pharmaceuticals Ltd Stocks COMPARISON

Financials( in Cr) Alembic Pharmaceuticals Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 888.20 1,516.00 1,564.75 4,588.60 1,109.55
% Change 0.59 0.34 1.31 -0.11 1.75
Mcap Cr 17,458.73 363,739.19 126,332.75 121,813.11 111,646.69
Revenue TTM Cr 5,652.62 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 341.99 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 28.41 36.34 29.68 76.10 28.94
1 Year Return 51.32 53.43 59.42 31.57 114.34
ROCE 7.20 16.79 14.76 19.30 16.25
ROE 7.12 16.46 10.66 14.89 14.05

Equity Capital: 4,370.47 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 34,088.77 -1,030.79
LAST 3M 113,155.52 -39,495.50
LAST 6M 184,812.44 -13,263.60
LAST 12M 291,038.85 99,015.20

Alembic Pharmaceuticals Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Alembic Pharmaceuticals Ltd., a pharmaceutical company engaged in manufacturing pharmaceutical products, substances, and intermediates, is recognised as a market leader in India for anti-infective drugs in the macrolides segment. The company was incorporated in 1907, with its headquarters in Vadodara. For FY 2021-2022, Alembic Pharmaceuticals Ltd. recorded a total revenue of Rs 5,356.25 crore, down 0.87% from the previous financial year, 2020-2021. On 10 October 2022, the company’s market capitalisation stood at Rs 12,014 crore.

    The company is listed on the Bombay Stock Exchange with the code 533573, and on the National Stock Exchange with the code APLLTD.

    Alembic Pharmaceuticals Ltd. manufactures and markets Indian formulations, international generics, and active pharmaceutical ingredients across the globe. During the quarter that ended in June 2022, the company reported a loss of Rs 65.88 crore after three consecutive quarters of profits.

    The company’s shareholding pattern at the end of the June 2022 quarter represented a promoter stake of 69.61%, a foreign institutional investor stake of 5.94%, a domestic institutional investor stake of 12.15%, and a public stake of 12.3%. The leading promoter was Nirayu Limited having a 35.63% stake. During the same quarter, the company’s mutual fund holdings decreased from 5.18% to 5.01%, and foreign institutional investor holdings also decreased from 6.02% to 5.94%.

    Mr Chirayu Amin is the company’s chairman and CEO. Mr Praniv Amin and Mr Shaunak Amin are the managing directors. The other members of the leadership team include Mr Raj Kumar Baheti, Mr Pranav Parikh, Mr K G Ramanathan, Mr Ashok Barat, Mr Paresh Saraiya, and Dr Archana Hingorani. The company’s auditors include K C Mehta & Co and K S Aiyar & Co. As of 30 June 2022, Alembic Pharmaceuticals Ltd.’s total outstanding shares were 19.66 crores.

    On 10 October 2022, Alembic Pharmaceuticals Ltd.’s share price closed at Rs 610.30 on BSE and at Rs 611.25 on NSE. The company’s 52-week high share price was Rs 864.05, and the 52-week low share price was Rs 577.75.

    As of September 2022, Union Liquid Fund had a 5.23% stake in Alembic Pharmaceuticals Ltd. The other mutual fund holdings include Kotak Small Cap Fund, DSP Midcap Fund, and DSP Healthcare Fund, with a 2.10%, 1.63%, and 1.39% stake, respectively.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose

Registered Address

Alembic Road, , Vadodara, Gujarat, 390003

Tel : 91-0265-2280550
Email : apl.investors:alembic.co.in
Website : http://www.alembic-india.com

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 533573
Book Closure Date (Month) :
BSE Group : A
ISIN : INE901L01018

FAQ’s on Alembic Pharmaceuticals Ltd Shares

You can buy Alembic Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Alembic Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 14, 2024 03:56 PM the closing price of Alembic Pharmaceuticals Ltd was Rs.888.20.

The latest PE ratio of Alembic Pharmaceuticals Ltd as of Jun 14, 2024 03:56 PM is 28.41

The latest PB ratio of Alembic Pharmaceuticals Ltd as of Jun 14, 2024 03:56 PM is 0.28

The 52-week high of Alembic Pharmaceuticals Ltd share price is Rs. 1,094.00 while the 52-week low is Rs. 588.20

According to analyst recommendations, Alembic Pharmaceuticals Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 14, 2024 03:56 PM, the market cap of Alembic Pharmaceuticals Ltd stood at Rs. 17,458.73.

Download App

Download Our App

Play Store App Store
market app